A b s t r a c t
The activated partial thromboplastin time (aPTT) is widely used as a screening coagulation test and for monitoring unfractionated heparin therapy. Various commercial reagents are available, with different performance characteristics, particularly responsiveness to the lupus anticoagulant (LA). Because aPTT reagent selection significantly affects the interpretation of results, we reviewed College of American Pathologists proficiency testing data involving approximately 4,000 coagulation laboratories, and conducted a survey of coagulation laboratories (n =
The clot-based activated partial thromboplastin time (aPTT) was first developed in 1954 as the recalcification time assay 1 and evolved to become the partial thromboplastin time (PTT) with the addition of a "platelet substitute," an extract of rabbit brain tissue composed of phospholipids called "cephalin." This was considered a "partial thromboplastin," because there was no tissue factor included. The assay became designated as "activated," when negatively charged particulate contact activators such as kaolin, silica, ellagic acid, or celite were added to improve responsiveness and reproducibility. 2 Many current aPTT reagents use soy-based synthetic phospholipids and nonsettling activators such as colloidal silica. 3 When an aPTT reagent is added to citrated platelet-poor plasma, it triggers in vitro clot formation by activating factor XII. 4 The aPTT is responsive to deficiencies in the intrinsic and/or common pathways, and will prolong with a significant single factor deficiency or multiple deficiencies of the common pathway. Manufacturers generally formulate reagents so that the aPTT will prolong when the activity of factors VIII, IX, or XI is reduced to approximately 30% (0.3 IU) or below. Fibrinogen levels usually have to fall below 100 mg/dL (2.94 μmol/L) before the aPTT will prolong. Laboratory operators may confirm aPTT responsiveness to factor deficiencies as a quality assurance practice.
From 1970 to the present, the aPTT has also been used to monitor the anticoagulant effect of unfractionated heparin, which decelerates coagulation by binding to antithrombin and inhibits most serine proteases, but most importantly, activated factor X (Xa) and thrombin (IIa). 5 To guide heparin therapy, laboratory operators establish a reagent-specific aPTT therapeutic range equivalent to 0.3 to 0.7 anti-Xa heparin units/mL. The target range must be verified or updated with each new lot of aPTT reagent, because the responsiveness to inhibition of factors Xa and IIa varies among reagents and reagent lots. 6 Lupus anticoagulant (LA) belongs to a family of "antiphospholipid antibodies," immunoglobulins that recognize phospholipid-bound proteins. LA has a prevalence of 1% to 2% in the unselected patient population. Although most LAs are transient and disappear within 12 weeks, chronic LA is associated with the potential for venous and arterial thrombosis. 7 Because of the heterogeneity of LA reactivity, complex laboratory testing strategies involving a panel of screening and confirmatory tests are required. [8] [9] [10] Screening for LA with an isolated aPTT is not recommended.
LA may prolong the aPTT because it partially neutralizes reagent phospholipids required for optimal clot formation. Thus, some manufacturers formulate low-phospholipid aPTT reagents to enhance detection of LA. 9 For instance, Siemens Actin FSL (Siemens Healthcare Diagnostics, Tarrytown, NY), Beckman-Coulter HemosIL aPTT-SP (Beckman Coulter, Brea, CA), and Stago PTT-LA (Diagnostica Stago, Parsippany, NJ) are low-phospholipid reagents that are especially responsive to LA, whereas Siemens Actin FS and Stago C.K. Prest are considered to exhibit relatively low responsiveness to LA; Stago STAPTT-LA and Beckman-Coulter HemosIlSynthASil, both formulated for automation, possess intermediate responsiveness to LA. When LA-responsive reagents are used to screen for intrinsic factor deficiency or to monitor heparin, prolongation secondary to LA will interfere with result interpretation. Importantly, prolongation in response to LA may be misinterpreted as a possible coagulation factor deficiency or, for patients receiving heparin or anticoagulation therapy with direct thrombin inhibitors (eg, lepirudin, dabigatran, and argatroban), can mislead clinicians to overestimate the level of anticoagulation, and erroneously provide insufficient anticoagulation therapy for the patient. Because a single aPTT reagent most often does not meet the clinical requirements of heparin/anticoagulation monitoring, coagulopathy screening, and LA screening, the present study was developed to learn whether laboratories select aPTT reagents based on their most common clinical needs.
Materials and Methods
Proficiency testing data from the College of American Pathologists (CAP) from 2008 to 2011 for a coagulationlimited survey were analyzed for aPTT reagent use. Approximately 3,800 to 4,000 laboratories participated in each testing event. In addition, a survey of coagulation laboratories was conducted in 2010 through a hemostasis Web site, The Fritsma Factor (www.fritsmafactor.com) to determine whether low, intermediate, and high LA-responsive aPTT reagents are being used appropriately. The Fritsma Factor is an interactive Web site that provides an open forum to access and share knowledge, information, and insight in the area of hemostasis. Content is managed independently by one of us (G.F.). Site design and infrastructure are supported by Precision BioLogic, Dartmouth, Canada. A total of 93 laboratories responded to the survey. Finally, a regional discussion was conducted among coagulation laboratory directors (n = 5) from New York and New Jersey in September 2010 to solicit opinions regarding the most appropriate and cost-effective use of aPTT reagents that have varying responsiveness to LA. When asked during the Web-based survey, "Does your laboratory use aPTT reagents with different responsiveness to lupus anticoagulant?" 66% of participants indicated a negative response, 32% positive, and 2% did not know. The subgroup of laboratories (32%) that used both LA-responsive reagents and aPTT reagents with low LA responsiveness further answered the following questions: "How do you use the aPTT reagent with low responsiveness to LA?" and "How do you use the aPTT reagent with high responsiveness to LA?" As summarized in ❚Table 3❚, low responsiveness reagents were appropriately used by most participants to screen for intrinsic coagulation factor deficiency and heparin monitoring. Reagents with high LA responsiveness were used appropriately, predominantly to screen for LA. However, even among the subgroup of laboratories that apparently recognized the advantage of using separate aPTT reagents with different LA responsiveness, a small number inappropriately used aPTT reagents with low LA responsiveness to screen for LA and reagents with high or moderate LA responsiveness to monitor for heparin and/or screen for factor deficiencies.
Results

Given the revised International Society on Thrombosis and Haemostasis (ISTH) guidelines for the detection of LA by clinical laboratories, 10 the survey further asked the opinion of all participants regarding the statement "A normal aPTT rules out the presence of a LA." As shown in ❚Table 4❚, most respondents (69%) appropriately disagreed with this statement. However, 31% of laboratories appear not to understand the specific requirements for LA testing, and thus are not able to provide proper consultation to clinicians whom they serve.
Many laboratories across North America (based on CAP proficiency testing exercises and study survey) use only a single reagent with moderate or high responsiveness to LA for automated aPTT testing. Therefore a regional discussion among laboratory directors from New York and New Jersey was convened to understand the reasons for this practice. Conference participants cited reagent availability and difficulty troubleshooting mismatched instrument/reagent combinations because of a lack of adequate peer group for comparison as well as reagent/analyzer compatibility as predominant concerns.
A prolonged aPTT often leads to the performance of additional tests, including an aPTT mixing study with pooled normal plasma to discriminate between the presence of a circulating anticoagulant and factor deficiency. Therefore the Fritsma Factor survey asked participants whether mixing studies were performed by their laboratories and what the turnaround time was for such testing. Of the respondents, 19% performed mixing studies reflexively when the aPTT was prolonged, whereas 54% performed them only when ordered by a physician, and 26% did not perform mixing studies (1% did not know). Among laboratories performing mixing studies, 60% provided results within 8 hours, 7% within 8 to 12 hours, and 17% within 12 to 24 hours. The remaining 16% of laboratories tested batches of samples and reported results after 24 hours or longer.
Discussion
LA testing challenges laboratory scientists with a unique problem. Transient LA is an innocent finding, but one that forces laboratory operators to follow up with expensive, complex, and time-consuming assays. Positive screening results also raise patient anxiety. Conversely, chronic LA is an established thrombosis risk factor associated with antiphospholipid syndrome, a cause of venous and arterial thrombosis, and obstetric complications. 7 A 2008 survey conducted by the North American Specialized Coagulation Laboratory Association demonstrated variable responsiveness of screening tests to LA, 12 underscoring the recommendation by the ISTH 8,10 that at least 2 different screening tests be performed to rule out the presence of an LA. In the current study, nearly 70% of study survey respondents agreed that an isolated normal aPTT result does not rule out the presence of an LA, and nearly all were aware that LA-responsive aPTT reagents should be used for LA testing. However, despite the coagulation laboratory community's general appreciation of LA interference with aPTT screening and heparin monitoring, results of our analysis show that most laboratories select moderate or high LA-responsive reagents on the basis of availability and adaptability to instrumentation without reference to reagent clinical use and efficacy.
Based on the findings of the present study, the following consensus recommendations are made:
1. The routine laboratory aPTT is useful for evaluating the intrinsic pathway of coagulation and some anticoagulants, and should be performed with a reagent that exhibits low responsiveness to LA. 2. A greater selection of commercial aPTT reagents with low LA responsiveness is needed to accommodate a greater variety of instrument/reagent combinations. 3. Special testing panels, including multiple phospholipidbased clotting assays, some of which may be aPTTbased, are required when LA screening is undertaken to assess thrombosis risk. Screening using a single aPTT assay is inadequate to rule out the presence of LA. 4. Further education of laboratory professionals and coagulation reagent manufacturers is needed to address clinical need and to increase awareness regarding the appropriate use and selection of aPTT reagents to improve patient care and laboratory efficiency.
